Synthesis and anti-HIV activity of D- and L-thietanose nucleosides

被引:32
作者
Choo, H
Chen, X
Yadav, V
Wang, JN
Schinazi, RF
Chu, CK [1 ]
机构
[1] Univ Georgia, Coll Pharm, Athens, GA 30602 USA
[2] Emory Univ, Sch Med, Vet Affairs Med Ctr, Atlanta, GA 30033 USA
关键词
D O I
10.1021/jm050912h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Various D- and L-thietanose nucleosides were synthesized from D- and L-Xylose. The four-membered thietane ring was efficiently synthesized by the cyclization of 1-thioacetyl-3-mesylate (4/38) under basic conditions. Condensation with various heterocyclic bases was conducted via Pummerer-type rearrangement to afford various nucleoside derivatives. Among the synthesized nucleosides, D-uridine (23), D-cytidine (24), D-5-fluorocytidine (25), and L-Cytidine (52) analogues showed moderate anti-HIV activity, with EC50 = 6.9, 1.3, 5.8, and 14.1 mu M, respectively. However, these four nucleoside analogues are cytotoxic in peripheral blood mononuclear and CEM cells. The other nucleosides are neither active nor cytotoxic. Interestingly,,,the oxetanocin A analogue 33 was not active. Comparison of the minimized reverse transcriptases (RTs) complexed with the corresponding triphosphates of the cytidine analogue 24 and the adenosine analogue 33 by molecular modeling studies showed that there is no difference in the binding mode of the triphosphate of the cytidine analogue 24 to the active site of HIV-1 RT from that of the triphosphate of the adenosine analogue 33. Modeling studies on the initial monophosphorylation step by deoxycytidine kinase showed that the catalytic efficiency of phosphorylation through a nucleophilic attack of the 4'-hydroxyl group of thietanose on the gamma-phosphate of ATP is diminished in the case Of L-cytidine analogue (52) due to the increased distance between the 4'-hydroxyl group and the gamma-phosphate.
引用
收藏
页码:1635 / 1647
页数:13
相关论文
共 48 条
[1]   Thiosugars, Part 3.: Preparation of methyl 2,3-di-O-mesyl-4,6-thioanhydro-α-D-galactopyranoside and methyl 2-O-mesyl-4,6-thioanhydro-α-D-gulopyranoside [J].
Adiwidjaja, G ;
Brunck, JS ;
Polchow, K ;
Voss, J .
CARBOHYDRATE RESEARCH, 2000, 325 (04) :237-244
[2]   EFFICACY OF A-73209, A POTENT ORALLY-ACTIVE AGENT AGAINST VZV AND HSV INFECTIONS [J].
ALDER, J ;
MITTEN, M ;
NORBECK, D ;
MARSH, K ;
KERN, ER ;
CLEMENT, J .
ANTIVIRAL RESEARCH, 1994, 23 (02) :93-105
[3]   MULTIPLE-DRUG EFFECT ANALYSIS WITH CONFIDENCE-INTERVAL [J].
BELENKII, MS ;
SCHINAZI, RF .
ANTIVIRAL RESEARCH, 1994, 25 (01) :1-11
[4]   Synthesis of [4,5-bis(hydroxymethyl)-1,3-dioxolan-2-yl]nucleosides as potential inhibitors of HIV [J].
Branalt, J ;
Kvarnstrom, I ;
Classon, B ;
Samuelsson, B .
JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (11) :3599-3603
[5]   Optically active cyclobutanone chemistry:: Synthesis of (-)-cyclobut-A and (±)-3′-epi-cyclobut-A [J].
Brown, B ;
Hegedus, LS .
JOURNAL OF ORGANIC CHEMISTRY, 1998, 63 (22) :8012-8018
[6]   Effects of fluorine substitution of cytosine analogues on the binding affinity to HIV-1 reverse transcriptase [J].
Chong, YH ;
Choo, H ;
Chu, CK .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) :437-440
[7]   Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: Molecular dynamics studies [J].
Chong, YH ;
Chu, CK .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (23) :3459-3462
[8]  
Chong Youhoon, 2002, Antivir Chem Chemother, V13, P115
[9]   Perspectives for the treatment of hepatitis B virus infections [J].
De Clercq, E .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 12 (02) :81-95
[10]   TOWARD IMPROVED ANTI-HIV CHEMOTHERAPY - THERAPEUTIC STRATEGIES FOR INTERVENTION WITH HIV-INFECTIONS [J].
DECLERCQ, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (14) :2491-2517